Aquestive Therapeutics, Inc. 8-K

What Happened

• Aquestive Therapeutics announced on March 16, 2026 that Lori J. Braender will step down from her roles as Chief Legal Officer and Chief Compliance Officer, effective April 2, 2026, and will cease being an executive officer while remaining employed to provide transition services through May 7, 2026 and serving as Corporate Secretary through at least year-end. The company appointed Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer effective April 2, 2026. A press release was issued March 20, 2026.

Key Details

• Separation and transition dates: separation agreement effective March 16, 2026; executive roles end April 2, 2026; transition pay continues through May 7, 2026.
• Cash and pay: Braender will receive a pro rata 2026 target annual bonus in cash plus monthly payments for 12 months following May 7, 2026 equal to 1/12 of the sum of her base salary and target annual bonus as in effect before May 7, 2026.
• Benefits and equity: continued group health and life insurance coverage for 12 months at levels for similarly situated executives; full and immediate vesting on May 7, 2026 of then-unvested stock options, RSUs, SARs, Restricted Stock and other equity awards (performance awards deemed achieved at target if performance period ends at/after May 7, 2026); vested options/SARs/exercisable awards will remain exercisable for at least five years after termination as Corporate Secretary or until award expiration.
• New Corporate Secretary terms: Braender will continue as Corporate Secretary under a new employment agreement at $15,000 per month and remain eligible for senior executive benefit plans.
• Change-in-control protection: Braender retains prior change-in-control severance protections per her September 10, 2018 agreement, calculated using salary and target bonus in effect before May 7, 2026.

Why It Matters

• Executive transition: investors should note a leadership change in legal and compliance with an experienced external hire (Thomas Zalewski) taking over CLO/CCO duties April 2, 2026, while the prior officer remains available for continuity as Corporate Secretary.
• Financial/compensation impact: the separation includes cash payments, continued benefits, accelerated equity vesting, and post-employment exercise windows that could have a one-time compensation and equity accounting impact; the company disclosed specific payout structure and continued insurance coverage, reducing transition risk.
• Governance continuity: retaining Braender as Corporate Secretary through year-end provides continuity for corporate governance and regulatory matters during the transition.